Introducing Symbravo

A New Era in Migraine Relief: Meet Symbravo

For the more than 39 million Americans who live with migraine, the release of a new treatment is always met with hope—and questions. In early 2025, the FDA approved Symbravo, a novel oral medication that brings together two well-established migraine therapies—meloxicam and rizatriptan—into a single, fast-acting tablet. Developed by Axsome Therapeutics, Symbravo is now available in pharmacies and may represent a new option for those seeking both rapid and sustained migraine relief.

So, what exactly is Symbravo? At its core, it’s a combination of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and rizatriptan, a triptan that targets serotonin receptors. While each of these medications has been used individually for years, Symbravo’s innovation lies in its dual-action design and proprietary MoSEIC® technology, which enhances the solubility and absorption of meloxicam for quicker therapeutic effect. The result is a single pill that works fast—and continues to work for hours after the initial dose.

Symbravo was tested in three major clinical trials—MOMENTUM, INTERCEPT, and MOVEMENT—covering more than 21,000 individual migraine attacks. The data are compelling. In one study involving patients with moderate-to-severe migraines, more than three-quarters of those treated with Symbravo did not need any additional "rescue" medication within 24 hours. Another trial showed that when taken at the earliest signs of migraine, Symbravo effectively reduced pain and associated symptoms like nausea, light sensitivity, and sound sensitivity—often within two hours. For many patients, the relief lasted up to 48 hours.

This combination approach isn't just about convenience, though that certainly helps. By targeting inflammation with meloxicam and serotonin pathways with rizatriptan, Symbravo offers a more comprehensive attack on migraine mechanisms. In fact, the drug outperformed rizatriptan alone in delivering sustained symptom relief in clinical settings.

Symbravo is approved for the acute treatment of migraine with or without aura in adults. It is not indicated for preventive use or for treating other types of headaches like cluster, hemiplegic, or basilar migraines. Patients are advised to take one tablet at the onset of a migraine, and not to exceed one dose in a 24-hour period. Unlike some triptans that allow for a second dose if the first is ineffective, Symbravo should not be repeated during the same attack.

As with any medication, there are risks. Because it contains an NSAID, Symbravo carries warnings about cardiovascular and gastrointestinal complications, particularly for patients with heart disease or a history of ulcers. The rizatriptan component may also pose risks for those with uncontrolled high blood pressure or certain neurological conditions. Common side effects reported include dizziness and drowsiness. And like other abortive migraine treatments, frequent use can increase the risk of medication-overuse headache (MOH).

Cost and access may be another consideration. While Symbravo provides the ease of a two-in-one solution, some patients may find that taking generic meloxicam and rizatriptan separately is more affordable, though not necessarily as fast-acting or long-lasting due to differences in formulation.

Still, for many, Symbravo offers a promising new option—particularly for those whose current treatments aren’t providing reliable relief. By combining two trusted medications in a modern, optimized form, it brings a fresh approach to an all-too-familiar problem.

If you suffer from migraine and are considering trying Symbravo, speak with your healthcare provider. They can help determine whether it’s a good fit for your symptoms, medical history, and treatment goals.